Harald Stenmark, from Department of Biochemistry, has become a member in the European Molecular Biology Organization (EMBO). A membership here is of great merit. EMBO runs a number of courses, seminars and grant programmes, and evaluate research quality. EMBO runs to journals.
From major journals, first or last author from the Institute for Cancer Research
Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L(2025) Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer Breast Cancer Res, 27(1), 131 DOI 10.1186/s13058-025-02082-x, PubMed 40660361
Chen Y, He L, Ianevski A, Nader K, Ruokoranta T, Linnavirta N, Miettinen JJ, Vähä-Koskela M, Vänttinen I, Kuusanmäki H, Kontro M, Porkka K, Wennerberg K, Heckman CA, Giri AK, Aittokallio T(2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia Cancer Res, 85(14), 2753-2768 DOI 10.1158/0008-5472.CAN-24-3840, PubMed 40354625
Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L(2025) Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer Breast Cancer Res, 27(1), 131 DOI 10.1186/s13058-025-02082-x, PubMed 40660361